Subscribe to our newsletter to receive the latest product updates and special offers

HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite
Theme 		Help

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Earnings

Review historical estimates and see whether a company has beaten or missed expectations.

NTBL

Notable Labs Ltd

Last Close
Jun 14 • 04:00PM ET
0.6800
Dollar change
-0.2100
Percentage change
-23.60 		%
Scroll to Statements
Index- P/E- EPS (ttm)-0.21 Insider Own48.46% Shs Outstand77.64M Perf Week-20.47%
Market Cap52.80M Forward P/E- EPS next Y-1.73 Insider Trans-0.42% Shs Float40.02M Perf Month-37.04%
Income-15.96M PEG- EPS next Q-0.43 Inst Own0.18% Short Float0.74% Perf Quarter-56.69%
Sales0.48M P/S109.99 EPS this Y56.74% Inst Trans-56.53% Short Ratio0.74 Perf Half Y-76.71%
Book/sh0.27 P/B2.49 EPS next Y-16.95% ROA-45.61% Short Interest0.30M Perf Year-92.38%
Cash/sh0.31 P/C2.18 EPS next 5Y- ROE-59.52% 52W Range0.71 - 11.20 Perf YTD-64.02%
Dividend Est.- P/FCF- EPS past 5Y-2.40% ROI-82.94% 52W High-93.93% Beta1.04
Dividend TTM- Quick Ratio4.63 Sales past 5Y- Gross Margin86.49% 52W Low-4.90% ATR (14)0.13
Dividend Ex-Date- Current Ratio4.63 EPS Y/Y TTM56.38% Oper. Margin-3398.54% RSI (14)34.02 Volatility15.54% 12.68%
Employees- Debt/Eq0.00 Sales Y/Y TTM-15.91% Profit Margin-3317.05% Recom1.00 Target Price7.00
Option/ShortNo / Yes LT Debt/Eq0.00 EPS Q/Q90.81% Payout- Rel Volume0.45 Prev Close0.89
Sales Surprise- EPS Surprise-3.85% Sales Q/Q-100.00% EarningsMay 16 Avg Volume403.24K Price0.68
SMA20-26.50% SMA50-34.88% SMA200-76.16% Trades Volume180,658 Change-23.60%
Date Action Analyst Rating Change Price Target Change
Jul-20-22Downgrade Oppenheimer Outperform → Perform
Jul-20-22Downgrade H.C. Wainwright Buy → Neutral
Jul-18-22Resumed Oppenheimer Outperform $5.50
Apr-28-22Initiated Chardan Capital Markets Buy $5
May-18-21Initiated Guggenheim Buy $7
Jun-27-19Initiated Oppenheimer Outperform
Mar-09-18Downgrade Chardan Capital Markets Buy → Neutral $25 → $3
Mar-08-18Downgrade Piper Jaffray Overweight → Neutral
Mar-08-18Downgrade H.C. Wainwright Buy → Neutral $3
Nov-06-17Reiterated Chardan Capital Markets Buy $20 → $25
Show Previous Ratings
May-24-24 09:55AM
Bears are Losing Control Over Notable Labs (NTBL), Here's Why It's a 'Buy' Now
(Zacks)
May-16-24 11:53AM
NTBL Stock Earnings: Notable Labs Misses EPS for Q1 2024
(InvestorPlace)
May-13-24 07:23AM
Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
(InvestorPlace)
May-09-24 04:05PM
Notable Labs to Participate in Fireside Chat at the Citizens JMP Securities Life Sciences Conference 2024
(GlobeNewswire) +24.37%
12:15PM
Fight Against Pancreatic Cancer Ramps Up as Market Size Revenues Expected to Exceed $36 Billion by 2036
(PR Newswire)
12:00PM Loading…
Apr-19-24 12:00PM
Notable Labs (NTBL) Upgraded to Buy: What Does It Mean for the Stock?
(Zacks)
Apr-12-24 01:53PM
NTBL Stock Earnings: Notable Labs Misses EPS for Q4 2023
(InvestorPlace)
08:00AM
Notable Labs Reports 2023 Financial Results and Provides a Business Update
(GlobeNewswire)
Apr-09-24 05:15PM
Notable Labs Presents the Design Plan for the PPMP-Enabled Phase 2 Trial with Volasertib for Relapsed/Refractory AML at AACR 2024
(GlobeNewswire) -5.37%
Apr-08-24 12:00PM
Notable Labs Presentation of Data Related to Innovations in the Use of Cryopreserved Samples in the PPMP Assay at AACR 2024 Expands the Potential of the Platform
(GlobeNewswire) -9.15%
Mar-05-24 04:35PM
Notable Labs to Present Two Posters at AACR 2024 on PPMP Platform
(GlobeNewswire)
Feb-22-24 08:00AM
Notable Advances Volasertib Phase 2 Program Utilizing Proprietary Predictive Precision Medicine Platform-Guided Enrollment
(GlobeNewswire)
Dec-18-23 08:00AM
Notable Reports Predictive Precision Medicine Platform (PPMP) Accurately Predicted Fosciclopirox Trial Outcome
(GlobeNewswire) -11.56%
Dec-13-23 12:00PM
Notable Labs Donates $60,000 to MDS Foundation to Accelerate Progress for Patients with Myelodysplastic Syndromes
(PR Newswire)
Dec-11-23 12:00PM
Notable Labs Funds Myelodysplastic Syndromes Foundation with $60,000 Grant
(PR Newswire) -5.05%
04:30PM Loading…
Dec-04-23 04:30PM
Notable Labs to Participate in JMP Securities Hematology and Oncology Summit
(GlobeNewswire)
Nov-14-23 04:15PM
Notable Labs Announces Filing of Form 10-Q for Third Quarter 2023
(GlobeNewswire) +7.92%
Nov-09-23 04:05PM
Notable Labs Announces JCO Precision Oncology Publication Demonstrating PPMP Potential to Identify Novel Drug Combinations in JMML
(GlobeNewswire)
Oct-16-23 01:01PM
Notable Labs Closes Merger Transaction With VBL Therapeutics
(GlobeNewswire) -8.77%
Oct-12-23 09:00AM
VBL Therapeutics Announces Results of Annual and Special Shareholder Meeting
(GlobeNewswire) -28.63%
Oct-04-23 08:00AM
VBL Therapeutics Reminds Shareholders to Vote in the Upcoming Annual and Special Shareholder Meeting
(GlobeNewswire)
Sep-06-23 08:00AM
VBL Therapeutics Announces that S-4 Registration Statement for Proposed Merger with Notable Labs Is Declared Effective by SEC
(GlobeNewswire) +8.06%
Aug-14-23 08:28AM
Vascular Biogenics: Q2 Earnings Snapshot
(AP Finance)
08:00AM
VBL Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
(GlobeNewswire)
May-15-23 06:08PM
Vascular Biogenics: Q1 Earnings Snapshot
(AP Finance)
04:01PM
VBL Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update
(GlobeNewswire)
Mar-17-23 06:37AM
Vascular Biogenics Full Year 2022 Earnings: US$0.42 loss per share (vs US$0.45 loss in FY 2021)
(Simply Wall St.)
Mar-14-23 08:00AM
VBL Therapeutics Reports Full Year 2022 Financial Results and Provides Corporate Update
(GlobeNewswire)
Mar-09-23 08:00AM
VBL Therapeutics Announces Closing of Sale of Manufacturing Facility and Certain Related Assets for $7.1 Million in Cash
(GlobeNewswire)
Feb-23-23 07:00AM
VBL Therapeutics and Notable Labs Announce Definitive Merger Agreement
(GlobeNewswire) +29.66%
08:00AM Loading…
Feb-16-23 08:00AM
VBL Therapeutics Announces Agreement to Sell Manufacturing Facility and Certain Related Assets for $7.1 Million in Cash
(GlobeNewswire)
Nov-29-22 05:43PM
13 Best Biotech Penny Stocks To Buy Now
(Insider Monkey)
Nov-14-22 07:55PM
Vascular Biogenics (VBLT) Reports Q3 Loss, Tops Revenue Estimates
(Zacks)
04:05PM
VBL Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update
(GlobeNewswire)
Nov-10-22 05:35PM
OYSTER PT PHARM (OYST) Reports Q3 Loss, Lags Revenue Estimates
(Zacks)
Sep-02-22 12:36PM
Axsome (AXSM) Starts Late-Stage Study of Migraine Drug AXS-07
(Zacks)
12:29PM
Pliant (PLRX) Receives Positive Review of IPF Study at Top Dose
(Zacks)
Sep-01-22 04:30PM
VBL Therapeutics Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
(GlobeNewswire) -5.20%
12:45PM
Sorrento (SRNE) Gets FDA Fast Track Tag for Back Pain Product
(Zacks)
Aug-15-22 05:35PM
Vascular Biogenics (VBLT) Reports Q2 Loss, Misses Revenue Estimates
(Zacks)
04:05PM
VBL Therapeutics Announces Second Quarter 2022 Financial Results and Corporate Process to Explore Strategic Options
(GlobeNewswire)
Aug-08-22 10:00AM
Analysts Estimate Vascular Biogenics (VBLT) to Report a Decline in Earnings: What to Look Out for
(Zacks) +6.55%
Aug-02-22 08:00AM
VBL Therapeutics Announces Workforce Reduction
(GlobeNewswire)
Jul-21-22 11:49AM
Vascular Biogenics (VBLT) Down, Ovarian Cancer Study Fails
(Zacks) -11.51%
Jul-20-22 07:35AM
Read Why VBL Therapeutics Shares Are Falling To a 52-Week Low
(Benzinga) -79.27%
Jul-19-22 04:01PM
VBL Therapeutics Announces Top-Line Data from Phase 3 OVAL Trial of Ofra-Vec in Patients with Platinum-Resistant Ovarian Cancer
(GlobeNewswire)
May-31-22 08:00AM
VBL Therapeutics to Participate in the Jefferies Healthcare Conference
(GlobeNewswire) -5.64%
May-17-22 08:15AM
Vascular Biogenics (VBLT) Reports Q1 Loss, Misses Revenue Estimates
(Zacks) +5.48%
07:00AM
VBL Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update
(GlobeNewswire)
May-16-22 08:15AM
Kala Pharmaceuticals (KALA) Reports Q1 Loss, Misses Revenue Estimates
(Zacks) +8.15%
May-12-22 05:45PM
ITeos Therapeutics, Inc. (ITOS) Surpasses Q1 Earnings and Revenue Estimates
(Zacks)
May-10-22 08:00AM
VBL Therapeutics to Report First Quarter 2022 Financial Results on May 17
(GlobeNewswire)
May-08-22 10:51AM
What Kind Of Shareholders Hold The Majority In Vascular Biogenics Ltd.'s (NASDAQ:VBLT) Shares?
(Simply Wall St.)
May-04-22 07:55AM
Editas Medicine (EDIT) Reports Q1 Loss, Tops Revenue Estimates
(Zacks)
May-03-22 08:55AM
Harmony Biosciences Holdings, Inc. (HRMY) Beats Q1 Earnings Estimates
(Zacks)
08:00AM
VBL Therapeutics to Participate in Upcoming Scientific and Industry Conferences in May
(GlobeNewswire)
Apr-28-22 04:05PM
VBL Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
(GlobeNewswire)
Apr-26-22 08:00AM
VBL Therapeutics Receives FDA Fast Track Designation for Ofra-Vec for the Treatment of Platinum-Resistant Ovarian Cancer
(GlobeNewswire) +8.97%
Apr-01-22 08:36AM
Fulcrum Therapeutics, Inc. (FULC) Stock Jumps 5.7%: Will It Continue to Soar?
(Zacks)
Mar-31-22 08:00AM
VBL Therapeutics to Host In-Person Key Opinion Leader Seminar on Ovarian Cancer
(GlobeNewswire)
Mar-24-22 03:04PM
Here's Why We're Watching Vascular Biogenics' (NASDAQ:VBLT) Cash Burn Situation
(Simply Wall St.)
Mar-23-22 09:25AM
Vascular Biogenics (VBLT) Reports Q4 Loss, Lags Revenue Estimates
(Zacks) +13.99%
07:00AM
VBL Therapeutics Reports Full Year 2021 Financial Results and Provides Corporate Update
(GlobeNewswire)
Mar-14-22 09:57AM
UPDATE -- VBL Therapeutics to Report Year-End 2021 Financial Results on March 23
(GlobeNewswire)
08:00AM
VLB Therapeutics to Report Year-End 2021 Financial Results on March 23
(GlobeNewswire)
Mar-08-22 08:00AM
VBL Therapeutics Announces Completion of Enrollment in OVAL Phase 3 Registration-Enabling Trial of Ofra-Vec in Ovarian Cancer and Unanimous Recommendation by Independent Data Safety Monitoring Committee to Continue Study as Planned
(GlobeNewswire)
Mar-03-22 08:00AM
VBL Therapeutics to Participate at March Investor Conferences
(GlobeNewswire)
Mar-01-22 05:45PM
Regenxbio (RGNX) Q4 Earnings and Revenues Beat Estimates
(Zacks)
Feb-15-22 04:05PM
VBL Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
(GlobeNewswire) +6.77%
Feb-02-22 08:00AM
VBL Therapeutics to Participate in the Guggenheim Oncology Conference and the 2022 BIO CEO & Investor Conference
(GlobeNewswire) -5.26%
Jan-18-22 08:00AM
VBL Therapeutics Announces Appointment of Matthew Trudeau as Chief Commercial Officer
(GlobeNewswire) -7.06%
Jan-06-22 08:10AM
VBL Therapeutics to Present at H.C. Wainwright BioConnect Virtual Conference
(GlobeNewswire)
Dec-28-21 09:19AM
BridgeBio (BBIO) Tumbles on Cardiomyopathy Candidate Failure
(Zacks)
Dec-20-21 07:30AM
VBL Therapeutics Selected for 17.5 Million of Funding from Horizon Europe EIC Accelerator Program
(GlobeNewswire) -6.91%
Dec-09-21 11:18AM
Reata (RETA) Falls on Negative Advisory Committee Outcome
(Zacks) -5.36%
Dec-07-21 10:26AM
Reata (RETA) Plunges on FDA Concerns for Kidney Failure Drug
(Zacks) +5.34%
Nov-22-21 10:48AM
Do Insiders Own Lots Of Shares In Vascular Biogenics Ltd. (NASDAQ:VBLT)?
(Simply Wall St.)
Nov-18-21 12:00PM
What Makes Vascular Biogenics (VBLT) a New Buy Stock
(Zacks)
Nov-15-21 12:25PM
Vascular Biogenics (VBLT) Reports Q3 Loss, Lags Revenue Estimates
(Zacks)
07:30AM
VBL Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update
(GlobeNewswire)
Nov-08-21 03:00PM
Will Vascular Biogenics (VBLT) Report Negative Q3 Earnings? What You Should Know
(Zacks)
08:00AM
VBL Therapeutics to Report Third Quarter Financial Results on November 15
(GlobeNewswire)
Oct-05-21 08:00AM
VBL Therapeutics Announces Appointment of Sam Backenroth as Chief Financial Officer and Establishes Operations in the United States
(GlobeNewswire)
Sep-17-21 07:00AM
VBL Therapeutics Announces Independent Data Safety Monitoring Committee Provides Clearance to Continue the OVAL Phase 3 Registration-Enabling Study of VB-111 in Ovarian Cancer
(GlobeNewswire)
Sep-10-21 07:00AM
VBL Therapeutics to Present at Upcoming Conferences
(GlobeNewswire)
Aug-30-21 07:00AM
VBL Therapeutics Resumes U.S. Enrollment in OVAL Phase 3 Trial as FDA Authorizes Clinical Use of VB-111 Batches Produced in Modiin Facility
(GlobeNewswire)
Aug-23-21 01:55PM
We Think Vascular Biogenics (NASDAQ:VBLT) Can Afford To Drive Business Growth
(Simply Wall St.)
Aug-16-21 08:25AM
Vascular Biogenics (VBLT) Reports Q2 Loss, Lags Revenue Estimates
(Zacks) -8.89%
07:00AM
VBL Therapeutics Reports Second Quarter 2021 Financial Results and Provides Corporate Update
(GlobeNewswire)
Aug-06-21 10:20AM
10 Biotech Penny Stocks to Buy According to Reddit
(Insider Monkey)
Aug-05-21 03:01PM
Will Vascular Biogenics (VBLT) Report Negative Q2 Earnings? What You Should Know
(Zacks)
07:00AM
VBL Therapeutics to Report Second Quarter Financial Results on August 16
(GlobeNewswire)
Jul-08-21 07:00AM
VBL Therapeutics Appoints Alison Finger and Michael Rice to its Board of Directors
(GlobeNewswire)
Jun-20-21 02:02PM
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vascular Biogenics Ltd. - VBLT
(GlobeNewswire)
Jun-17-21 02:51PM
Vascular Biogenics, Ltd. Investors: Company Investigated by the Portnoy Law Firm
(GlobeNewswire)
Jun-16-21 05:00AM
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vascular Biogenics Ltd. - VBLT
(PR Newswire)
Jun-15-21 07:00AM
VBL Therapeutics Provides Update on OVAL, a Phase 3 Registration Enabling Study of VB-111 in Ovarian Cancer
(GlobeNewswire) -11.61%
Jun-03-21 07:00AM
VBL Therapeutics Announces Addition of Progression Free Survival as a Second Primary Endpoint in OVAL, a Phase 3 Registration Enabling Study of VB-111 in Ovarian Cancer
(GlobeNewswire) +10.46%
May-20-21 07:00AM
VBL Therapeutics to Provide an Update on the OVAL Phase 3 Registration Enabling Study of VB-111 in Ovarian Cancer at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting
(GlobeNewswire) +7.66%
May-11-21 08:35AM
Vascular Biogenics (VBLT) Reports Q1 Loss, Lags Revenue Estimates
(Zacks)
Notable Labs Ltd. engages in the development of predictive medicines for patients with cancer. The company was founded in June 2014 and is headquartered in Foster City, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
FR Capital Holdings, L.P.Former 10% OwnerJan 02 '24Sale1.8950,00094,670880,489Jan 03 05:00 PM
FR Capital Holdings, L.P.10% OwnerDec 29 '23Sale1.836,00010,990930,489Jan 02 05:00 PM
FR Capital Holdings, L.P.10% OwnerDec 28 '23Sale2.0121,50043,146936,489Jan 02 05:00 PM
FR Capital Holdings, L.P.10% OwnerDec 27 '23Sale2.0820,03341,695957,989Dec 28 05:00 PM
FR Capital Holdings, L.P.10% OwnerDec 26 '23Sale2.1611,45624,766978,022Dec 28 05:00 PM
FR Capital Holdings, L.P.10% OwnerDec 22 '23Sale2.4145,000108,284989,478Dec 26 05:00 PM
FR Capital Holdings, L.P.10% OwnerDec 21 '23Sale2.512,8677,1911,034,478Dec 26 05:00 PM
open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR
affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2024 FINVIZ.com. All Rights Reserved.